December 04, 2025
Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood pressure medication, according to a Wednesday filing.
November 12, 2025
What was set to be the first bellwether case in the sprawling multidistrict litigation over contaminated blood pressure medication Valsartan was decided Monday when a New Jersey federal judge excluded as "pure speculation" the plaintiff's medical expert who testified that the drug caused a patient's liver cancer.
April 08, 2025
Patients and insurers who claim they were ripped off when purchasing the contaminated blood pressure medication Valsartan won't be able to argue that the drug was worthless as a matter of law, a New Jersey federal judge overseeing the multidistrict litigation has ruled, casting doubt that the plaintiffs will secure a full refund for their purchase.
August 05, 2024
Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. told a New Jersey federal court Friday that sanctions authorizing two adverse jury instructions in multidistrict litigation over generic drugs contaminated with carcinogens should be overturned, arguing the plaintiffs did not allege the bad faith required for such a harsh penalty.
May 14, 2024
Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. has been hit with sanctions after its chief executive officer failed to sit for a court-ordered deposition in sprawling multidistrict litigation taking place in New Jersey over generic drugs that U.S. authorities say were contaminated with carcinogens.
February 08, 2023
A New Jersey federal judge on Wednesday certified classes of consumers and insurers who claim they lost money by purchasing the contaminated blood pressure drug Valsartan, as well as two classes of consumers seeking medical monitoring for cancer potentially caused by the drug.
April 05, 2022
A New Jersey federal judge ruled Tuesday that multidistrict litigation against drug manufacturers, pharmacies and wholesalers over carcinogens in blood pressure drugs can expand to include out-of-state litigants and warranty claims under laws in nearly two dozen jurisdictions.
December 22, 2021
A New Jersey federal judge backed a special master's order that Zhejiang Huahai Pharmaceutical Co. Ltd. must produce documents it sought to shield in multidistrict litigation over blood pressure drugs such as valsartan, warning that parties can't exploit uncertainties in foreign state secrets laws to thwart U.S. lawsuits.
June 22, 2021
The special master in multidistrict litigation alleging that pharmaceutical companies sold generic drugs containing the active ingredient valsartan that were tainted with carcinogens ruled on Tuesday that the president of Zhejiang Huahai Pharmaceutical Co. Ltd. can't be blocked from giving a deposition in the case.
January 29, 2021
A New Jersey federal judge said Friday he won't toss fraud claims against drug manufacturers, but will toss the claims against wholesalers and pharmacies, in multidistrict litigation alleging they took part in distributing generic drugs containing the active ingredient valsartan that were tainted with carcinogens.